Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. NASDAQ: MEDX announced today that the following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as well as for anti-PD-1 and anti-CD70 antibody candidates for cancer treatment, are expected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 30-June 3, 2008 in Chicago:

    Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

    -- "Antitumor response and new lesions in advanced melanoma patients on
       ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:
       Immunotherapy Session) -- Poster presentation and discussion from 2:00
       p.m. to 6:00 p.m. local time on Friday, May 30, 2008.

    -- "Long-term survival of patients with advanced melanoma who received
       ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction
       dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy
       Session) - Poster presentation and discussion from 2:00 p.m. to 6:00
       p.m. local time on Friday, May 30, 2008.

    -- "Potential immune biomarkers of gastrointestinal toxicities and
       efficacy in patients with advanced melanoma treated with ipilimumab
       with or without prophylactic budesonide" (Abstract #3022, Developmental
       Therapeutics: Immunotherapy Session) -- Poster presentation and
       discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,
       2008.

    -- "Novel efficacy criteria for antitumor activity to immunotherapy using
       the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"
       (Abstract #3008, Developmental Therapeutics: Immunotherapy
       Session) -- Oral presentation beginning at 4:30 p.m. local time one
       Saturday, May 31, 2008.

    -- "Effect of prior treatment status on the efficacy and safety of
       ipilimumab monotherapy in treatment-naive and previously treated
       patients with advanced melanoma" (Abstract #9055, Melanoma
       Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time
       on Saturday, May 31, 2008.

    -- "An analysis of the effectiveness of specific guidelines for the
       management of ipilimumab-mediated diarrhea/colitis: prevention of
       gastrointestinal perforation and/or colectomy" (Abstract #9063,
       Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.
       local time on Saturday, May 31, 2008.

    -- "Model-based evaluation of ipilimumab dosage regimen in patients with
       advanced melanoma" (Abstract #9073, Melanoma Session) -- Poster
       presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May
       31, 2008.

    -- "Safety and efficacy of ipilimumab with or without prophylactic
       budesonide in treatment-naive and previously treated patients with
       advanced melanoma" (Abstract #9010, Melanoma Session) -- Oral
       presentation beginning at 10:15 a.m. local time on Sunday, June 1,
       2008.

    -- "Efficacy and safety of ipilimumab induction and maintenance dosing in
       patients with advanced melanoma who progressed on one or more prior
       therapies" (Abstract #9021, Melanoma Session) -- Poster presentation
       and discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June
       1, 2008.

    -- "Disease control and long-term survival in chemotherapy-naive patients
       with advanced melanoma treated with ipilimumab (MDX-010) with or
       without dacarbazine" (Abstract #9022, Melanoma Session) -- Poster
       presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on
       Sunday, June 1, 2008.

    -- "Dose effect of ipilimumab in patients with advanced melanoma: results
       from a phase 2, randomized, dose-ranging study" (Abstract #9025,
       Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.
       to 6:00 p.m. local time on Sunday, June 1, 2008.

    -- "Prolonged survival in objective responders to ipilimumab therapy"
       (Abstract #20004) --  Publication only.


    Response and Safety Data of Ipilimumab in Prostate

    -- "Phase 1 trial of ipilimumab (IPI) alone and in combination with
       radiotherapy (XRT) in patients with metastatic castration resistant
       prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for
       Patients with Prostate Cancer Session) -- Oral presentation beginning
       at 11:30 a.m. local time on Monday, June 2, 2008.

    -- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate
       cancer and ipilimumab in patients with metastatic hormone-refractory
       prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)
       -- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on
       Saturday, May 31, 2008.

Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs

    -- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal
       antibody, in patients with selected refractory or relapse malignancies"
       (Abstract #3006, Developmental Therapeutics: Immunotherapy
       Session) -- Oral presentation beginning at 4:00 p.m. local time on
       Saturday, May 31, 2008.

    -- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in
       combination with ixabepilone in preclinical tumor models" (Abstract
       #3048, Developmental Therapeutics: Immunotherapy Session) -- Poster
       presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
       2008.

    -- "Effect of a fully human anti-CD70 antibody on apoptosis and
       dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"
       (Abstract #3073, Developmental Therapeutics: Immunotherapy
       Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time
       on Sunday, June 1, 2008.

More information about the ASCO Annual Meeting may be found at www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

Company News On-Call: http://www.prnewswire.com/comp/108265.html /